Literature DB >> 23500782

Improved quantification of HIV-1-infected CD4+ T cells using an optimised method of intracellular HIV-1 gag p24 antigen detection.

Hongbing Yang1, Elisabeth Yorke, Gemma Hancock, Genevieve Clutton, Nellia Sande, Brian Angus, Redmond Smyth, Johnson Mak, Lucy Dorrell.   

Abstract

The capacity of CD8+ T cells to inhibit HIV-1 replication in vitro strongly correlates with virus control in vivo. Post-hoc evaluations of HIV-1 vaccine candidates suggest that this immunological parameter is a promising benchmark of vaccine efficacy. Large-scale analysis of CD8+ T cell antiviral activity requires a rapid, robust and economical assay for accurate quantification of HIV-1 infection in primary CD4+ T cells. Detection of intracellular HIV-1 p24 antigen (p24 Ag) by flow cytometry is one such method but it is thought to be less sensitive and quantitative than p24 Ag ELISA. We report that fixation and permeabilisation of HIV-infected cells using paraformaldehyde/50% methanol/Nonidet P-40 instead of a conventional paraformaldehyde/saponin-based protocol improved their detection across multiplicities of infection (MOI) ranging from 10(-2) to 8×10(-5), and by nearly two-fold (p<0.001) at the optimal MOI tested (10(-2)). The frequency of infected cells was strongly correlated with p24 Ag release during culture, thus validating its use as a measure of productive infection. We were also able to quantify infection with a panel of HIV-1 isolates representing the major clades. The protocol described here is rapid and cost-effective compared with ELISA and thus could be a useful component of immune monitoring of HIV-1 vaccines and interventions to reduce viral reservoirs.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23500782     DOI: 10.1016/j.jim.2013.03.001

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  19 in total

1.  CD8 T Cell Virus Inhibition Assay Protocol.

Authors:  Yinyan Xu; Ann Marie Weideman; Maria Abad-Fernandez; Katie R Mollan; Sallay Kallon; Shahryar Samir; Joanna A Warren; Genevieve Clutton; Nadia Roan; Adaora A Adimora; Nancie Archin; JoAnn Kuruc; Cindy Gay; Michael G Hudgens; Nilu Goonetilleke
Journal:  Bio Protoc       Date:  2022-03-20

2.  HLA-E-restricted, Gag-specific CD8+ T cells can suppress HIV-1 infection, offering vaccine opportunities.

Authors:  Hongbing Yang; Margarida Rei; Simon Brackenridge; Elena Brenna; Hong Sun; Shaheed Abdulhaqq; Michael K P Liu; Weiwei Ma; Prathiba Kurupati; Xiaoning Xu; Vincenzo Cerundolo; Edward Jenkins; Simon J Davis; Jonah B Sacha; Klaus Früh; Louis J Picker; Persephone Borrow; Geraldine M Gillespie; Andrew J McMichael
Journal:  Sci Immunol       Date:  2021-03-25

3.  Analytical Advances in the Ex Vivo Challenge Efficacy Assay.

Authors:  Nicola Richardson-Harman; Robert Parody; Peter Anton; Ian McGowan; Gustavo Doncel; Andrea Ries Thurman; Carolina Herrera; Kattayoun Kordy; Julie Fox; Karen Tanner; Glenn Swartz; Charlene S Dezzutti
Journal:  AIDS Res Hum Retroviruses       Date:  2016-12-16       Impact factor: 1.723

4.  Real-Time Killing Assays to Assess the Potency of a New Anti-Simian Immunodeficiency Virus Chimeric Antigen Receptor T Cell.

Authors:  Françoise Haeseleer; Karsten Eichholz; Semih U Tareen; Nami Iwamoto; Mario Roederer; Frank Kirchhoff; Haesun Park; Afam A Okoye; Lawrence Corey
Journal:  AIDS Res Hum Retroviruses       Date:  2020-11-05       Impact factor: 1.723

5.  Broad HIV epitope specificity and viral inhibition induced by multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults.

Authors:  Jakub Kopycinski; Peter Hayes; Ambreen Ashraf; Hannah Cheeseman; Francesco Lala; Justyna Czyzewska-Khan; Aggeliki Spentzou; Dilbinder K Gill; Michael C Keefer; Jean-Louis Excler; Patricia Fast; Josephine Cox; Jill Gilmour
Journal:  PLoS One       Date:  2014-03-07       Impact factor: 3.240

6.  Elimination of Latently HIV-infected Cells from Antiretroviral Therapy-suppressed Subjects by Engineered Immune-mobilizing T-cell Receptors.

Authors:  Hongbing Yang; Sandrine Buisson; Giovanna Bossi; Zoë Wallace; Gemma Hancock; Chun So; Rebecca Ashfield; Annelise Vuidepot; Tara Mahon; Peter Molloy; Joanne Oates; Samantha J Paston; Milos Aleksic; Namir J Hassan; Bent K Jakobsen; Lucy Dorrell
Journal:  Mol Ther       Date:  2016-06-06       Impact factor: 11.454

7.  Reliable Estimation of CD8 T Cell Inhibition of In Vitro HIV-1 Replication.

Authors:  Yinyan Xu; Ann Marie Weideman; Maria Abad-Fernandez; Katie R Mollan; Sallay Kallon; Shahryar Samir; Joanna A Warren; Genevieve Clutton; Nadia Roan; Adaora A Adimora; Nancie Archin; JoAnn Kuruc; Cindy Gay; Michael G Hudgens; Nilu Goonetilleke
Journal:  Front Immunol       Date:  2021-06-30       Impact factor: 7.561

8.  Aviremia 10 Years Postdiscontinuation of Antiretroviral Therapy Initiated During Primary Human Immunodeficiency Virus-1 Infection and Association With Gag-Specific T-Cell Responses.

Authors:  Sabine Kinloch-de Loes; Lucy Dorrell; Hongbing Yang; Gareth A D Hardy; Sabine Yerly; Cristina Cellerai; Linos Vandekerckhove; Ward De Spielgelaere; Eva Malatinkova; Willie Wee Lee Koh; Margaret A Johnson
Journal:  Open Forum Infect Dis       Date:  2015-11-23       Impact factor: 3.835

9.  Identification of effective subdominant anti-HIV-1 CD8+ T cells within entire post-infection and post-vaccination immune responses.

Authors:  Gemma Hancock; Hongbing Yang; Elisabeth Yorke; Emma Wainwright; Victoria Bourne; Alyse Frisbee; Tamika L Payne; Mark Berrong; Guido Ferrari; Denis Chopera; Tomas Hanke; Beatriz Mothe; Christian Brander; M Juliana McElrath; Andrew McMichael; Nilu Goonetilleke; Georgia D Tomaras; Nicole Frahm; Lucy Dorrell
Journal:  PLoS Pathog       Date:  2015-02-27       Impact factor: 6.823

10.  A Subset of CD4/CD8 Double-Negative T Cells Expresses HIV Proteins in Patients on Antiretroviral Therapy.

Authors:  Laura K DeMaster; Xiaohe Liu; D Jake VanBelzen; Benjamin Trinité; Lingjie Zheng; Luis M Agosto; Stephen A Migueles; Mark Connors; Lidia Sambucetti; David N Levy; Alexander O Pasternak; Una O'Doherty
Journal:  J Virol       Date:  2015-11-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.